Almac is pleased to announce the expansion of our drug product Pharmaceutical Development services with the creation of a new non-GMP formulation development facility and two new analytical ...
A future of long-term, minimally toxic immunotherapy personalized to the cellular level is on the horizon—but only if manufacturers have the means to produce these therapies within a GMP environment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results